New Hope for Lung Cancer Patients with FDA Approval of Gefitinib
In July 15, the U. S. Food and Drug (FDA) Administration approved IRESSA (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations with an exon 19 deletion or exon 21 (L858R) substitution. The approval is based on
